Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,652,310
  • Shares Outstanding, K 92,370
  • Annual Sales, $ 490,730 K
  • Annual Income, $ -25,550 K
  • EBIT $ -63 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.86
  • Price/Sales 7.71
  • Price/Cash Flow 116.34
  • Price/Book 32.83

Options Overview Details

View History
  • Implied Volatility 58.34% (-1.64%)
  • Historical Volatility 105.59%
  • IV Percentile 25%
  • IV Rank 7.50%
  • IV High 220.62% on 03/19/26
  • IV Low 45.18% on 09/19/25
  • Expected Move (DTE 28) 4.62 (11.67%)
  • Put/Call Vol Ratio 2.55
  • Today's Volume 9,204
  • Volume Avg (30-Day) 5,695
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 105,247
  • Open Int (30-Day) 68,838
  • Expected Range 34.92 to 44.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 6
  • High Estimate $0.15
  • Low Estimate $-0.61
  • Prior Year $-0.47
  • Growth Rate Est. (year over year) +36.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.15 +51.20%
on 03/20/26
43.31 -8.70%
on 04/14/26
+11.51 (+41.06%)
since 03/16/26
3-Month
26.15 +51.20%
on 03/20/26
43.31 -8.70%
on 04/14/26
+11.67 (+41.87%)
since 01/16/26
52-Week
13.88 +184.87%
on 06/18/25
43.31 -8.70%
on 04/14/26
+24.97 (+171.38%)
since 04/16/25

Most Recent Stories

More News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on April 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting...

TVTX : 39.54 (-3.44%)
Stocks Rally on a Push for Diplomacy to End US-Iran War

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.81%. June E-mini...

ALK : 41.15 (-3.27%)
MSTR : 148.94 (+3.76%)
GOOGL : 336.02 (-0.33%)
UAL : 95.03 (+0.81%)
AAPL : 263.40 (-1.14%)
BE : 210.06 (-1.77%)
C : 129.34 (-1.78%)
CVX : 188.15 (+1.75%)
GLXY : 24.43 (+1.62%)
HPQ : 19.72 (+2.55%)
$IUXX : 26,333.00 (+0.49%)
COIN : 199.82 (+2.00%)
Stocks Rally on US-Iran Peace Hopes and Cooler PPI Growth

The S&P 500 Index ($SPX ) (SPY ) today is up +0.77%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM26...

MSTR : 148.94 (+3.76%)
BLK : 1,024.95 (-2.26%)
GOOGL : 336.02 (-0.33%)
UAL : 95.03 (+0.81%)
AAPL : 263.40 (-1.14%)
BE : 210.06 (-1.77%)
C : 129.34 (-1.78%)
CVX : 188.15 (+1.75%)
GLXY : 24.43 (+1.62%)
HPQ : 19.72 (+2.55%)
$IUXX : 26,333.00 (+0.49%)
COIN : 199.82 (+2.00%)
Stocks Climb on US-Iran Peace Talk Optimism and a Favorable PPI Report

The S&P 500 Index ($SPX ) (SPY ) today is up +0.39%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.76%. June E-mini S&P futures (ESM26...

BLK : 1,024.95 (-2.26%)
MSTR : 148.94 (+3.76%)
UAL : 95.03 (+0.81%)
C : 129.34 (-1.78%)
BE : 210.06 (-1.77%)
GLXY : 24.43 (+1.62%)
HPQ : 19.72 (+2.55%)
$IUXX : 26,333.00 (+0.49%)
COIN : 199.82 (+2.00%)
ZNM26 : 111-100 (+0.08%)
MSFT : 420.26 (+2.20%)
CRWV : 119.56 (+0.73%)
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER,...

TVTX : 39.54 (-3.44%)
LGND : 223.24 (-0.82%)
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS

FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome Additional indication for FILSPARI...

TVTX : 39.54 (-3.44%)
Travere: Q4 Earnings Snapshot

Travere: Q4 Earnings Snapshot

TVTX : 39.54 (-3.44%)
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter ...

TVTX : 39.54 (-3.44%)
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets....

TVTX : 39.54 (-3.44%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting...

TVTX : 39.54 (-3.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 42.20
2nd Resistance Point 41.10
1st Resistance Point 40.32
Last Price 39.54
1st Support Level 38.44
2nd Support Level 37.34
3rd Support Level 36.56

See More

52-Week High 43.31
Last Price 39.54
Fibonacci 61.8% 32.07
Fibonacci 50% 28.60
Fibonacci 38.2% 25.12
52-Week Low 13.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.